Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors

PURPOSE: To assess the maximum-tolerated dose, toxicity, and pharmacokinetics of DE-310, a macromolecular prodrug of the topoisomerase I inhibitor exatecan (DX-8951f). in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Patients received DE-310 as a 3-hour infusion once every 2 weeks (dose, 1.0-2.0 mg/m(2)) or once every 6 weeks (dose, 6.0-9.0 mg/m(2)). Because pharmacokinetics revealed a drug terminal half-life exceeding the 2 weeks administration interval, the protocol was amended to a 6-week interval between administrations also based on available information from a parallel trial using an every 4 weeks schedule. Conjugated DX-8951 (the carrier-linked molecule), and the metabolites DX-8951 and glycyl-DX-8951 were assayed in various matrices up to 35 days post first and second dose. RESULTS: Twenty-seven patients were enrolled into the study and received a total of 86 administrations. Neutropenia and grade 3 thrombocytopenia, and grade 3 hepatotoxicity with veno-occlusive disease, were dose-limiting toxicities. Other hematologic and nonhematologic toxicities were mild to moderate and reversible. The apparent half-life of conjugated DX-8951, glycyl-DX-8951, and DX-8951 was 13 days. The area under the curve ratio for conjugated DX-8951 to DX-8951 was 600. No drug concentration was detectable in erythrocytes, skin, and saliva, although low levels of glycyl-DX-8951 and DX-8951 were detectable in tumor biopsies. One patient with metastatic adenocarcinoma of unknown primary achieved a histologically proven complete remission. One confirmed partial remission was observed in a patient with metastatic pancreatic cancer and disease stabilization was noted in 14 additional patients. CONCLUSIONS: The recommended phase II dose of DE-310 is 7.5 mg/m(2) given once every 6 weeks. The active moiety DX-8951 is released slowly from DE-310 and over an extended period, achieving the desired prolonged exposure to this topoisomerase I inhibitor

Development of a microfluidic confocal fluorescence detection system for the hyphenation of nano-LC to on-line biochemical assays

One way to profile complex mixtures for receptor affinity is to couple liquid chromatography (LC) on-line to biochemical detection (BCD). A drawback of this hyphenated screening approach is the relatively high consumption of sample, receptor protein and (fluorescently labeled) tracer ligand. Here, we worked toward minimization of sample and reagent consumption, by coupling nano-LC on-line to a light-emitting diode (LED) based capillary confocal fluorescence detection system capable of on-line BCD with low-flow rates. In this fluorescence detection system, a capillary with an extended light path (bubble cell) was used as a detection cell in order to enhance sensitivity. The technology was applied to a fluorescent enhancement bioassay for the acetylcholine binding protein, a structural analog of the extracellular ligand-binding domain of neuronal nicotinic acetylcholine receptors. In the miniaturized setup, the sensitive and low void volume LED-induced confocal fluorescence detection system operated in flow injection analysis mode allowing the measurement of IC(50) values, which were comparable with those measured by a conventional plate reader bioassay. The current setup uses 50 nL as injection volume with a carrier flow rate of 400 nL/min. Finally, coupling of the detection system to gradient reversed-phase nano-LC allowed analysis of mixtures in order to identify the bioactive compounds present by injecting 10 nL of each mixture

<i>Fasciola hepatica</i> Surface Coat Glycoproteins Contain Mannosylated and Phosphorylated N-glycans and Exhibit Immune Modulatory Properties Independent of the Mannose Receptor

<div><p>Fascioliasis, caused by the liver fluke <i>Fasciola hepatica</i>, is a neglected tropical disease infecting over 1 million individuals annually with 17 million people at risk of infection. Like other helminths, <i>F</i>. <i>hepatica</i> employs mechanisms of immune suppression in order to evade its host immune system. In this study the N-glycosylation of <i>F</i>. <i>hepatica’s</i> tegumental coat (FhTeg) and its carbohydrate-dependent interactions with bone marrow derived dendritic cells (BMDCs) were investigated. Mass spectrometric analysis demonstrated that FhTeg N-glycans comprised mainly of oligomannose and to a lesser extent truncated and complex type glycans, including a phosphorylated subset. The interaction of FhTeg with the mannose receptor (MR) was investigated. Binding of FhTeg to MR-transfected CHO cells and BMDCs was blocked when pre-incubated with mannan. We further elucidated the role played by MR in the immunomodulatory mechanism of FhTeg and demonstrated that while FhTeg’s binding was significantly reduced in BMDCs generated from MR knockout mice, the absence of MR did not alter FhTeg’s ability to induce SOCS3 or suppress cytokine secretion from LPS activated BMDCs. A panel of negatively charged monosaccharides (i.e. GlcNAc-4P, Man-6P and GalNAc-4S) were used in an attempt to inhibit the immunoregulatory properties of phosphorylated oligosaccharides. Notably, GalNAc-4S, a known inhibitor of the Cys-domain of MR, efficiently suppressed FhTeg binding to BMDCs and inhibited the expression of suppressor of cytokine signalling (SOCS) 3, a negative regulator the TLR and STAT3 pathway. We conclude that <i>F</i>. <i>hepatica</i> contains high levels of mannose residues and phosphorylated glycoproteins that are crucial in modulating its host’s immune system, however the role played by MR appears to be limited to the initial binding event suggesting that other C-type lectin receptors are involved in the immunomodulatory mechanism of FhTeg.</p></div

FhTeg binding to dendritic cells is mediated by MR and is carbohydrate and calcium dependent.

<p><b>A-B:</b> MR-transfected CHO cells (A) and BMDCs (B) were stimulated with and without inhibitors, i.e. EGTA (10mM), anti-MR (1 μg ml^-1), mannan (A: 100 μg ml^-1;B: 1 mg/mL), GalNAc-4S (A: 1mM; B: 25 mM), for 45 min prior to stimulation with fluorescently labelled FhTeg (A: 1–10 μg ml^-1; B: 5 μg/mL) for 45 min. Fluorescently labelled BSA was also used as control. FhTeg binding to cells was assessed by flow cytometry and reported in bar chart format. Data shown is the mean ± SD of one representative experiment; the experiment was repeated 2–3 times, **, <i>p</i> ≤ 0.01; ***, <i>p</i> ≤ 0.001 compared to FhTeg. <b>C-D:</b> BMDCs were stimulated with fluorescently labelled FhTeg (10μg ml^-1, green) or BSA (<u>10g</u> ml^-1, green)) for 45 min prior to paraformaldehyde fixation and mounting with DAPI (blue); Scale bar: 25μm.</p

The immune properties of FhTeg are independent of the MR receptor.

<p><b>A</b>: BMDCs were stimulated with mannan for 30 min prior to incubation with FhTeg for 2.5 h. Total RNA was extracted, and after reverse transcription cDNA was analyzed with qPCR for SOCS3. RNA expression was normalized to GAPDH and actin control genes. <b>B:</b> BMDCs were pre-incubated with mannan prior stimulation with PBS or FhTeg (10μg) before addition of LPS (100ng ml^-1) for 18 h. IL12p70 levels were measured with commercial ELISA kits. Data are presented as the mean ± SEM of two independent experiments. ***<i>p</i> ≤ 0.001; ****<i>p</i> ≤ 0.0001 compared to LPS group. <b>C,D:</b> BMDCs isolated from MR-knockout mice were stimulated with fluorescently labelled FhTeg or BSA (10μg ml^-1, green) for 45 min prior to paraformaldehyde fixation. FhTeg binding to cells was assessed by flow cytometry and reported in bar chart format. <b>E:</b> BMDCs isolated from MR-knockout mice were stimulated with FhTeg (10μg) for 2.5 h. Total RNA was extracted, and after reverse transcription cDNA was analyzed with qPCR for SOCS3. RNA expression was normalized to GAPDH and actin control genes. <b>F.</b> BMDCs derived from MR knockout mice were stimulated with <b>PBS</b> or FhTeg (10μg) before addition of LPS (100ng ml^-1) for 18 h. IL12p70 levels were measured with commercial ELISA kits. Data are presented as the mean ± SEM of two independent experiments. *<i>p</i> ≤ 0.05, **, <i>p</i> ≤ 0.01; ***, <i>p</i> ≤ 0.001.</p

MALDI-FT-ICR-MS analysis of FhTeg N-glycans indicates the presence of phosphorylated glycan species.

<p><b>A:</b> FT-ICR-MS spectrum indicating the phosphorylated glycans identified by accurate mass determination with external calibration and additional comparison with the internal confirmed oligomannose glycans. <b>B:</b> Zoom region showing the high resolution separation between the Man₆GlcNAc₂ glycan and a phosphorylated glycan of almost identical mass. <b>C:</b> The scatter plot indicates the deviation of the measured <i>m/z</i> from the calculated <i>m/z</i> of phosphorylated glycans in comparison with hypothetical sulphated glycans and the oligomannosyl glycans also present in the spectrum.</p

FhTeg preparation is rich in oligomannose and truncated complex type <i>N-</i>glycans carrying fucose or sulfate/phosphate moieties.

<p>Fh tegumental antigens were digested with trypsin followed by PNGase F treatment. Released N-glycans were subsequently labelled with 2-AA and analysed by MALDI-TOF-MS in the negative ion-reflector mode. Signals are labelled with monoisotopic masses. Most abundant <i>N</i>-glycan structures are annotated in the spectrum while minor peaks are reported in the supplementing material (<a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0004601#pntd.0004601.s004" target="_blank">S1 Table</a>). The signal at <i>m/z</i> 1582.8 [M-H]^- is annotated according to MALDI-TOF/TOF-MS analysis.</p

FhTeg <i>N-</i>glycans carry core fucose and are sulphated/phosphorylated on terminal <i>N</i>-acetylglucosamine and mannose residues.

<p>The sulphated/phosphorylated glycan observed at <i>m/z</i> 1313.6 [M-H]^- in <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0004601#pntd.0004601.g001" target="_blank">Fig 1</a> was analysed by MALDI-TOF- MS/MS. Differences in monosaccharides and functional groups content are indicated by double headed arrows.</p